- Matica Biotechnology has signed a commercial manufacturing agreement with a US-based clinical-stage biotech company.
- The CDMO will provide viral vector GMP production, technology transfer, and process scale-up to support BLA submission and commercial supply.
Matica Biotechnology, Inc. (Matica Bio) has announced a new strategic agreement with a clinical-stage biotech company in the United States. The contract covers commercial manufacturing of viral vectors to advance a novel therapy targeting a serious and underserved disease area.
Under the agreement, Matica Bio will deliver technology transfer, process scale-up, analytical testing, and commercial-scale GMP manufacturing. These services will support the programme’s Biologics License Application (BLA) submission and long-term commercial supply.
Paul Kim, CEO of Matica Bio, said: “This collaboration reflects Matica Bio’s ability to support advanced therapeutic development from early development stage through to commercial manufacturing, all under strict regulatory compliance.”
The Texas-based CDMO will leverage its proprietary MatiMax™ cell line and advanced analytical capabilities, including empty/full capsid ratio analysis, to support the partnership. The company stated that its expertise will help deliver successful outcomes for complex cell and gene therapy programmes.
